Related Experiment Video

Updated: Mar 25, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.7K

Validating the disruption of proliferating cell nuclear antigen interactions in the development of targeted cancer

Shanna J Smith1, Robert J Hickey2, Linda H Malkas1

  • 1a Beckman Research Institute at City of Hope , Department of Molecular and Cellular Biology , Duarte , CA , USA.

Cancer Biology & Therapy
|February 19, 2016
PubMed

Insights

A novel peptide inhibitor targeting the interdomain connector loop of proliferating cell nuclear antigen (PCNA) effectively disrupts DNA replication and polymerase delta activity, offering a new strategy for cellular function regulation.

Area of Science:

  • Molecular Biology
  • Biochemistry
  • Cell Biology

Background:

  • DNA replication and repair involve numerous proteins interacting with proliferating cell nuclear antigen (PCNA).
  • The interdomain connector loop (IDCL) of PCNA is crucial for protein interactions and cellular function regulation.
  • Previous research indicated a peptide (caPeptide) mimicking the PCNA IDCL can inhibit DNA replication.

Purpose of the Study:

  • To confirm the caPeptide's ability to disrupt DNA replication in both intact cells and in vitro.
  • To investigate the effect of caPeptide on polymerase delta activity.
  • To develop and validate an assay for the disruption of PCNA-polymerase delta interaction.

Main Methods:

  • Intact cell and in vitro DNA replication assays were used to assess caPeptide's efficacy.
  • Polymerase delta activity was measured following caPeptide treatment.
  • Surface plasmon resonance (SPR) assay was developed to validate protein-protein interaction disruption.

Main Results:

  • The caPeptide successfully inhibited DNA replication in both cellular and in vitro models.
  • caPeptide treatment led to decreased polymerase delta activity, correlating with reduced DNA replication.
  • An SPR assay confirmed caPeptide disrupts the interaction between PCNA and polymerase delta.

Conclusions:

  • The caPeptide is a potent inhibitor of DNA replication by disrupting PCNA-mediated protein interactions.
  • The study validates caPeptide's mechanism of action and its impact on polymerase delta.
  • This research provides a foundation for developing targeted therapies modulating DNA replication processes.
Keywords:
Cancer therapeuticsDNA polymerase δDNA replicationcompetition kineticsproliferating cell nuclear antigen (PCNA)surface plasmon resonance (SPR)

More Related Videos

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

2.2K
Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K